



CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

Education

Undergraduate: Baylor University, Waco, TX
Medical Doctor: Baylor College of Medicine, Houston, TX

Post-Doctoral Training

Flexible Internship: Scott United States Air Force Medical Center, Scott Air Force Base, IL
Resident in Diagnostic Radiology: Wilford Hall United States Air Force Medical Center, San Antonio, TX
Resident in Nuclear Medicine: Wilford Hall United States Air Force Medical Center, San Antonio, TX

Board Certification

1984: American Board of Nuclear Medicine
1982: American Board of Radiology (Diagnostic)

Professional Experience

2016 - Present: Online Radiology Medical Group Inc., an affiliate of Onrad, Inc., Riverside, CA
2007-Present: Tennessee Valley VA Healthcare System, Nashville, TN
2007-2010: Vanderbilt University Medical Center, Nashville, TN
2001-2007: University of Arkansas for Medical Sciences, Little Rock, AR
2001-2002: SemperCare Hospital and Baptist Healthcare, Little Rock, AR
1992-2002: University of Arkansas for Medical Sciences, Little Rock, AR
1989-2002: Baptist HealthCare of Arkadelphia, Arkadelphia, AR
1989-2002: Baptist Memorial Medical Center, North Little Rock, AR
1989-2002: Baptist Medical Center, Little Rock, AR
1989-2002: Radiology Consultants of Little Rock, PA, Little Rock, AR
1989-2000: Rebsamen Regional Medical Center, Jacksonville, AR
1986-1989: 13th Air Force Medical Center, Clark Air Base, Republic of the Philippines

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

1986-1989: Consultant to Pacific Air Force Surgeon General

1984-1986: Uniformed Services University of the Health Sciences, Bethesda, MD

1984-1986: Malcom Grow United States Air Force Medical Center, Andrews Air Force Base, Washington, DC

1974-1989: USAF Officer, Highest Rank: Lt. Col selectee, Honorable Discharge

1971-1974: USAF Full Scholarship Recipient, Baylor University, Waco, TX

Professional Societies

American College of Radiology
American College of Nuclear Medicine
Radiological Society of North American
SNMMI (formerly Society of Nuclear Medicine)

Published Articles

Journal Articles – Peer Reviewed

1. **Walker RC**, Weiss DW, Purnell GL, Forte KF. Positron emission tomography scanning: a primer. *Journal of the Arkansas Medical Society* 99(4):119-121, 2002.
2. **Walker RC**, Zigler SS. PET practice in nuclear pharmacy. *Journal American Pharmacists Association* 32:S42-3, 2003.
3. Tian E, Zhan F, **Walker R**, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt/ β -catenin signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. *New England Journal of Medicine* 349:2483-2494, 2003.
4. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, **Walker R**, Crowley J. Treatment of multiple myeloma. *Blood* 103:20-32, 2004.
5. **Walker RC**, Purnell GL, Jones-Jackson LB, Thomas KL, Brito JA, Ferris EJ. Introduction to PET imaging with emphasis on biomedical research. *NeuroToxicology* 2004; 25(4): 533-542
6. Angtuaco EJC, Fassas AB, **Walker RC**, Sethi R, Barlogie B. Multiple Myeloma: Clinical review and diagnostic imaging. *Radiology* 2004; 231:11-23

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

7. Miceli M, Atoui R, Thertulien R, Barlogie B, Anaissie E, **Walker R**, Jones- Jackson L. Deep septic thrombophlebitis: an unrecognized cause of relapsing bacteremia in patients with cancer. Letter to the editor. *Journal Clinical Oncology*; 2004:1529-31.
 8. **Walker RC**, Barlogie B, Shaughnessy J. re:. *N Eng J of Med* 349:2483-2494, 2003, Letter to the Editor, *N Eng J Med* 350: 14:1465.
 9. Miceli MH, Jones-Jackson LB, **Walker RC**, Talamo G, Barlogie B, Anaissie EJ. Diagnosis of Infection of Implantable Central Venous Catheters by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography, *Nuclear Medicine Communications*, 2004 25(8):813-8.
 10. Miceli MH, Atoui R, **Walker R**, Mahfouz T, Mirza N, Diaz J, Tricot B, Barlogie B, Anaissie E. Diagnosis of deep septic thrombophlebitis in cancer patients by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography scanning: a preliminary Report. *Journal of Clinical Oncology* 2004; 22:1949-1956.
- Maxwell C, Rasmussen E, Zhan F, Keats J, Adamia S, Strachan E, Crainie M, **Walker R** , Belch A, Pilarski L, Barlogie B, Shaughnessy J Jr., Reiman T. RHAMM expression and isoform balance predicts aggressive disease and poor survival in multiple myeloma., *Blood* 2004; 104: 1151-1158.
12. **Walker RC**. Focus on myeloma and plasma cell disorders. *Idrugs March* 2005; 8(3): 189-92.
 13. Kelly T, Suva LJ, Huang Y, MacLeod V, Miao MV, **Walker RC**, Sanderson RD. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. *Cancer Research* July 2005; 65(13): 5778-5784.
 14. Talamo G, Angtuaco E, **Walker RC**, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. *Journal of Clinical Oncology* Aug 2005; 23(22):5217-23.
 15. Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, **Walker R**, Graziutti ML, Purnell G, Fassas A, Tricot G, Barlogie B, Anaissie E. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. *Journal of Clinical Oncology* Nov 2005; 23:7857-7863
 16. Jones-Jackson L, **Walker R**, Purnell G, McLaren SG, Skinner RA, Thomas JR, Suva LJ, Anaissie E, Miceli M, Nelson CL, Ferris EJ, Smeltzer M. Early detection of bone infection and differentiation from post-surgical inflammation using 2-deoxy-2-[¹⁸F]-fluoro-D-glucose positron emission tomography (FDG- PET) in an animal model. *Journal of Orthopedic Research* 2005; 23: 1484-489.

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

17. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman R, Tricot G, van Rhee F, **Walker R**, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. The molecular classification of multiple myeloma based on gene expression signatures of CD248-selected plasma cells. *Blood* 2006; 108: 2020-2028.
18. Epstein J, **Walker R**. Myeloma and bone disease: The dangerous tango. *Clinical Advances in Hematology & Oncology* 2006; 4: 300-306.
19. Yaccoby S, Wezeman MG, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems And a myelomatous mouse model. *Haematologica* Feb, 2006; 91:192-199
20. **Walker R**, Barlogie B, Tricot G, Haessler J, Anaissie E, Shaughnessy J, Epstein J, van Hemert R, Erdem E, Hoening A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangarie M, Pineda-Roman M, Mohiuddin A, Yaccobyk S, Sawyer J, Angtuaco, EJ. Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. *J Clin Oncol* 2007; 25: 1121-1128.
21. Yaccoby S, Wen L, Zhan F, **Walker R**, Barlogie B, Shaughnessy J. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth *in vivo*. *Blood* 2007; 109:2106-2111.
22. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, vanRhee F, Sawyer J, Alsayed Y, **Walker R**, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to Chromosome 1. *Blood* 2007; 109: 2276-2284.
23. King DL, Stack BC, Spring PM, **Walker R**, Bodenner DL. The Incidence of Thyroid Carcinoma in Fluorodeoxyglucose Positron Emission Tomography (PET) Positive Thyroid Incidentalomas. *Otolaryngology – Head and Neck Surgery* (2007); 137(3): 400-404.
24. **Walker RC**, Jones-Jackson LB, Martin W, Habibi MR, Delbeke D. New Imaging Tools for the Diagnosis of Infection. *Future Microbiol* 2007; 2(5): 527-554.
25. Bartel TB, Haessler J, Brown TYL, Shaughnessy JD Jr., van Rhee F, Anaissie E, Alpe T, Angtuaco E, **Walker R**, Epstein J, Crowley J, Barlogie B. F-18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. *Blood* 2009; 114(10): 2068-2076. (DOI 10.1182/blood-2009-03-213280).
26. Deppen, SA, Putnam, JB, Andrade, G Speroff, T., Nesbitt, JC, Lambright, ES, Massion, PP, **Walker, R** Grogan, EL. Accuracy of FDG-PET to Diagnose Lung Cancer in a Region of Endemic Granulomatous Disease. *The Annals of thoracic surgery* 2011;92:428-33. doi:10.1016/j.athoracsur.2011.02.052

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

27. Grogan EL, Weinstein JJ, Deppen SA, Putnam JB, Nesbitt JC, Lambright ES, **Walker R**, Dittus RS, Massion PP. Thoracic operations for pulmonary nodules are frequently not futile in patients with benign disease. *J Thorac Oncol* 2011; 6: 1720-1725. doi:10.1097/JTO.0b013e318226b48a.
28. Callison J Clay, **Walker RC**, Massion Pierre P. Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics. *Journal of Lung Cancer*. December 2011 2011;10(2):69-76
29. **Walker R**, Brown TL, Jones-Jackson LB, De Blanche L, Bartel T. Continuing Education: Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias. *J Nucl Med* 2012; 53:1091-1101 DOI: 10.2967/jnumed.111.098830 PMID: 22693310
30. McKinley ET, Smith RA, Tanksley JP, Washington Mary Kay, **Walker Ronald**, Coffey Robert J, Manning H Charles ¹⁸F-FLT-PET to predict pharmacodynamics and clinical response to cetuximab therapy in Menetrier's disease. *Ann Nucl Med* 2012; 26(9):757-63: epub: DOI 10.1007/s12149-012-0636-x
31. **Walker Ronald**, Smith Gary T, Liu Eric, et al. Measured human dosimetry of ⁶⁸Ga-DOTATATE. *J Nucl Med* 2013; 54: 1-6 DOI: 10.2967/jnumed.112.114165 PMID: 23516312
32. Islam Shaheen, **Walker Ronald C**. Advanced Imaging (PET and MRI) and Image-guided Biopsy in Initial Staging and Monitoring of Therapy of Lung Cancer. *The Cancer Journal* 2013; 19: 208-216 DOI: 10.1097/PPO.0b013e318295185f PMID:23708067
33. Deppen, S.A., Blume, J., Aldrich, M.C., Fletcher, S.A., Massion, P.P., **Walker, R.**, Chen, H., Speroff, T., Necessary, C.A., Pinkerman, R., Lambright, E.S., Nesbitt, J.C., Putnam, J.B., and Grogan, E.L. (2014) Predicting lung cancer prior to surgical resection in patients with lung nodules. *Journal of Thoracic Oncology* 2014;9:1477-84 PMID: 25170644
34. Deppen Stephan, Blume Jeffrey, Aldrich Melinda, Fletcher Sarah, Massion Pierre, **Walker Ronald**, Chen Heidi, Speroff Theodore, Necessary Catherine, Pinkerman Rhonda, Lambright Eric, Nesbitt Jonathan, Putnam Joe, Grogan Eric. "Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: A meta-analysis." *JAMA*, 2014; 312:1227-36. PMID: 25247519
35. Gifford A, Towse TF, Walker RC, Avison MJ, Welch EB. Human brown adipose tissue depots automatically segmented by positron emission tomography/computed tomography and registered magnetic resonance images. *J Vis Exp*. 2015(96). PMID: 25741672.
36. Blumhardt R, Wolin E, Phillips W, Salman U, **Walker R**, Stack B, Metter D. Current Controversies in the Initial Post-Surgical Radioiodine Therapy for Thyroid Cancer: A Narrative Review. *Endocr Relat Cancer* 2014;21(6):R473-484 PMID:25277792
37. Massion PP, **Walker RC**. Indeterminate pulmonary nodules: risk for having or for developing lung cancer? *Cancer Prev Res* 2014;7(12);1173-1178. PMID: 25348855.

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

38. McKinley ET, Watchmaker JM, Bapsi Chakravarthy A, Meyerhardt JA, Engelman JA, **Walker RC**, Kay Washington M, Coffey RJ, Charles Manning H. [F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. *Ann Nucl Med*. 2015. PMID: 2589948
39. Sherrod AM, Hari P, Mosse CA, **Walker RC**, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. *Bone Marrow Transplant*. 2015. PMID: 26191950
40. Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, **Walker R**, Sandler M, Berlin J, Liu EH. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. *Am J Clin Pathol* 2015;143:398-404. PMID: 25696798
41. Smith GT, Rahman AR, Li M, Moore B, Gietema H, Veronesi G, Massion PP, **Walker RC**. Reproducibility of Volumetric Computed Tomography of Stable Small Pulmonary Nodules with Implications on Estimated Growth Rate and Optimal Scan Interval. *PLoS One*. 2015;10(9):e0138144. PMID: 26379272
42. Gifford Aliya, **Walker Ronald**, Towse Theodore F, Welch E Brian. Correlations between quantitative fat-water magnetic resonance imaging and computed tomography in human subcutaneous white adipose tissue. *J. Med. Imag.* 2015;2(4):046001. doi: 10.1117/1.JMI.2.4.
43. Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging and treatment management of neuroendocrine tumors. *J Nucl Med* 2016; 57(5); 708-14. PMID: 26769865.
44. Deppen SA, Blume J, Bobbey AJ, Graham MM, Lee P, Delbeke D, **Walker RC**. ⁶⁸Ga-DOTATATE compared to ¹¹¹In-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. *J Nucl Med* 2016;57(6):872-8. PMID: 26769864
45. Gifford Aliya, Towse Theodore, **Walker Ronald**, Avison Malcolm, and Welch E Brian. Characterizing Active and Inactive Brown Adipose Tissue in Adult Humans Using PET-CT and MR Imaging. *Am J Physiol Endocrinol Metab* 2016; in press.

BOOK CHAPTERS

1. Barlogie B, Shaughnessy J, Epstein J, Sanderson R, Anaissie E, **Walker R**, Tricot G, Plasma Cell Myeloma in Williams Hematology, 7th Edition, Lichtman et al (Eds), McGraw-Hill, 2006.
2. **Walker R**, Jones-Jackson L, Rasmussen E, Miceli M, Angtuaco EJC, Van Rhee F, Tricot GJ, Epstein J, Anaissie EJ, Barlogie B. *PET and PET/CT Imaging in multiple myeloma, solitary plasmacytoma, MGUS and other plasma cell dyscrasias*. In: Positron Emission Tomography: Clinical Practice 2nd Edition. Valk, Delbeke, Bailey (Eds), Springer, 2006

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

3. Jessop A, **Walker R**, Delbeke D. *Tumors of the Central Nervous System* In: Hybrid PET/CT and SPECT/CT Imaging – A Teaching File Editors: Dominique Delbeke and Ora Israel (Eds), Springer, 2009
4. **Walker R**, Jones-Jackson L, Jessop A, Delbeke D. *PET/CT Imaging of Lung Cancer* In: Hybrid PET/CT and SPECT/CT Imaging – A Teaching File Editors: Dominique Delbeke and Ora Israel (Eds), Springer, 2009
5. **Walker R**, Jones-Jackson L, Jessop A, Delbeke D. *PET/CT Imaging of Melanoma* In: Hybrid PET/CT and SPECT/CT Imaging – A Teaching File Editors: Dominique Delbeke and Ora Israel (Eds), Springer, 2009
6. Delbeke D, **Walker R**. *PET/CT Imaging of Colorectal Cancer* In: Hybrid PET/CT and SPECT/CT Imaging – A Teaching File Editors: Dominique Delbeke and Ora Israel (Eds), Springer, 2009
7. Delbeke D, **Walker R**. *PET/CT Imaging of Hepatobiliary Cancer* In: Hybrid PET/CT and SPECT/CT Imaging – A Teaching File Editors: Dominique Delbeke and Ora Israel (Eds), Springer, 2009
8. **Walker R**, Jones-Jackson L, Bartel T, Brown T, Barlogie B. *Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and other Plasma Cell Dyscrasias* In: Myeloma Bone Disease: G David Roodman (Ed), Humana Press, 2010.
9. **Walker R**, Miceli, M, Jones-Jackson L. *PET-CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, and Related Plasma Cell Dyscrasias* In: Clinical PET-CT in Radiology Ed: Paul Shreve, MD and David W. Townsend, PhD, Springer Science+Business Media, LLC, 2011
10. Jones-Jackson LB, **Walker RC**, Delbeke D. Liver metastases from colorectal cancers. In: Keiding S, Sørensen S, eds. *Functional and Molecular Imaging in Hepatology*. Sharjah, UAE: Bentham Science Publishers; 2012:104–119

Continuing Education Enduring Materials (Peer Reviewed)

1. Oncology CT Module of the Abdomen. James McCarley, MD; **Ronald Walker**, MD; Lavanya Kalla, MD; Laurie Jones-Jackson, MD; Twyla Bartel, DO; Victoria Major, MD; Hemendra Shah, MD; Dominique Delbeke, MD, PhD. **Society of Nuclear Medicine's and the American Board of Radiology's** Life-long Learning and Self-Assessment (LLSAP) program. Available online for CME and maintenance of certification, www.snm.org, www.acr.org.
2. Oncology CT Module of the Pelvis. Leah Braswell, MD; **Ronald Walker**, MD; Lavanya Kalla, MD; Laurie Jones-Jackson, MD; Twyla Bartel, DO; Victoria Major, MD; Hemendra Shah, MD; Dominique Delbeke, MD, PhD. **Society of Nuclear Medicine's and the American Board of Radiology's** Life-long Learning and Self-Assessment (LLSAP) program. Available online for CME and maintenance of certification, www.snm.org, www.acr.org.
3. Introduction to Oncology CT of the Head and Neck. Twyla Bartel, DO; **Ronald Walker**, MD, Laurie Jones-Jackson, MD, Major, Victoria, MD, Hemendra Shah, MD, Dominique Delbeke, MD, PhD. **Society of Nuclear Medicine's and the American Board of Radiology's** Life-long Learning and Self-Assessment (LLSAP) program. Available online for CME and maintenance of certification, www.snm.org, www.acr.org.
4. Introduction to Oncology CT of the Chest. **Ronald Walker**, MD, Lavanya Kalla, MD, Lorraine De Blanche, MD, Chandra Donepudi, MD, Laurie Jones- Jackson, MD, Twyla Bartel, DO, Victoria Major, MD, Hemendra Shah, MD, Dominique Delbeke, MD, PhD. **Society of Nuclear Medicine's and the American Board of Radiology's** Life-long Learning and

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

Self-Assessment (LLSAP) program. Available online for CME and maintenance of certification, www.snm.org, www.acr.org.

Presentations and Published Abstracts

1. Oral Presentation: Scintigraphic Evaluation of Patients with Renal Transplantation. 28th Annual Southwestern Chapter Meeting, Society of Nuclear Medicine, Oklahoma City, Oklahoma. 1983. (Abstract: *Clinical Nuclear Medicine*. March 1983 Supplement.)
2. Oral Presentation: Scintigraphic Evaluation with Technetium-labeled IDA Compounds in Patients from the Southwest Region, With and Without Prior Sinicalide. 29th Annual Southwestern Chapter Meeting, Society of Nuclear Medicine, Houston, Texas, 1984. (Abstract: *Clinical Nuclear Medicine*. March 1984 Supplement.)
3. Poster Presentation: Determination of Spatial Alignment and Collimator Angle for Rotating Slanhole Collimators. 30th Annual Southwestern Chapter Meeting, Society of Nuclear Medicine, New Orleans, Louisiana. March 1985. (Abstract: *Clinical Nuclear Medicine*. 1985:26(3) 327. Supplement.)
4. Poster Presentation: Measurement of Geometric Parameters of a Rotating Slanhole Collimator. XIV ICMBE and VII ICMP, Espoo, Finland, 1985. (Abstract published in the proceedings of the XIV ICMBE and VII ICMP, page 1363, 1985.)
5. Skeletal Scintigraphy, Annual Meeting, Arkansas Chapter of the American College of Radiology, Little Rock, Arkansas, October 6, 1990. (Abstract published in syllabus for the Arkansas ACR Chapter meeting, October 6, 1990.)
6. Oral Presentation: Works in Progress: High Dose Double Injection TL-201 Stress Test Scintigraphy with 3D Surface Mapped and SPECT Image Reconstruction with a State-of-the-Art Single Head Anger GAMMA Camera (Orbiter, Siemens Corp.) and a modern Nuclear Medicine Computer System (Pinnacle Computer, Medasys Corp). Presented at the 38th Annual Meeting, Southwestern Chapter of the Society of Nuclear Medicine March 12, 1993, Dallas, Texas. Abstract published in *Clinical Nuclear Medicine*; 1993:8(2) p. 177, Supplement.
7. Poster Presentation: 38th Annual Meeting Southwestern Chapter of Society of Nuclear Medicine. Reversible Defect with TL-201 Imaging Caused by Aortic Valvular Regurgitation. March 14, 1993. Abstract published in *Clinical Nuclear Medicine*: 1993:8(2)180, Supplement.
8. Oral Presentation: Evaluation of 134 Consecutive Patients for the Presence of Significant Coronary Artery Disease (CAD) with a Single- Headed SPECT Gamma Camera with Dual Isotope Imaging. 42nd Annual Meeting of the Southwestern Chapter of the Society of Nuclear Medicine Meeting, New Orleans, LA, April 11-13, 1997. Abstract published in *Clinical Nuclear Medicine*; 1997:22(3)202, Supplement.
9. Poster Presentation: Magnetic Resonance Imaging (MRI) as Part of Staging Work-Up for Newly Diagnosed Multiple Myeloma (MM): > 5 Focal Lesions and LDH Elevation Identify Inferior Survival in 402 Patients Receiving Total Therapy II (TTII). 44th ASH Annual Meeting, Philadelphia, PA, December 6-10, 2002. Philadelphia, PA, December 6-10, 2002.

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

10. Poster Presentation: Prospective Evaluation of 460 Patients from Total Therapy II—Identification of Characteristics on Baseline MRI, Examinations of Prognostic Significance, Importance of Focal Lesions (FL) in Multiple Myeloma (MM). IXth International Workshop on Multiple Myeloma, Salamanca, Spain, May 23-27 2003. (Abstract published in *The Hematology Journal*; 2003:4(1) S171.)
11. Oral presentation (given by J Shaughnessy, lead author): Secretion of Wnt signaling antagonists by myelomatous plasma cells blocks osteoblast differentiation and induces IL-6 secretion by osteoblast precursor cells thereby contributing to both lytic bone lesions and myeloma cell growth. American Society of Hematology (ASH) Meeting in San Diego, CA, December 6-9, 2003.
12. Poster presentation. FDG-PET has a significant impact on the diagnosis and management of infection in patients with hematological cancer: a study of 73 infections in 67 patients. American Society of Hematology (ASH) Meeting in San Diego, CA, December 6-9, 2003.
13. Poster presentation: Superior Differentiation of Osteomyelitis from Post-Surgical Inflammation Using FDG PET Scanning Compared to Standard X-rays. 50th Annual Meeting of the Orthopaedic Research Society, San Francisco, California, March 7-10, 2004.
14. Poster presentation: Anti-IL6 Antibody based strategies improve the management of HIV Negative Castleman's Disease. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
15. Poster presentation: KIR-Ligand Mismatched Natural Killer Cells Effectively Kill Primary Myeloma and Myeloma Cell Lines. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
16. Poster presentation: Rapid Response to Treatment of Multiple Myeloma Detected with FDG PET Scanning in Multiple Myeloma – Early Results from Total Therapy III. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
17. Poster Presentation: ¹⁸F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
18. Oral Presentation (given by Fenghuang Zhan, lead author): The Transcriptome of Multiple Myeloma (MM) Defines Disease Subgroups with Distinct Genetic and Clinical Features. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
19. Poster Presentation: Biomarkers of Myeloma-Associated Lytic Bone Disease Using SELDI-TOF MS. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
20. Poster Presentation: FDG PET Functional Imaging in Multiple Myeloma – Clinically Important Caveats, Pitfalls, and Pearls. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
21. Poster Presentation: Avascular Necrosis of Bone after Therapy for Multiple Myeloma: A Study of 561 Consecutive

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

Patients. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.

22. Oral Presentation: Diagnostic Imaging of Multiple Myeloma – FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
23. Published abstract: MRI-Detectable Focal Lesions (FL) in Multiple Myeloma (MM) at Relapse Frequently Involve Novel Sites Not Involved at Diagnosis. American Society of Hematology (ASH) Meeting, San Diego, California, December 4-7, 2004.
24. Oral presentation (given by Ernest J. Ferris, lead author). Introduction to PET-CT Imaging. Eastern Radiological Society Meeting, Manele Bay, Princeville, and Kaopaula Bay, Hawaii, October 18-26, 2005.
25. Poster Presentation: Whole Body Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): More Than Just Cancer Detection—An Important Tool in Finding Infection: A Pictorial Review. 91st Annual Meeting Radiological Society of North America (RSNA), Chicago, Illinois, November 27-December 2, 2005.
26. Poster Presentation: Extramedullary Manifestations of Multiple Myeloma: A Great Mimic—Pictorial Essay of the Imaging Features with Pathological Correlation. (Awarded Certificate of Merit). 91st Annual Meeting Radiological Society of North America (RSNA), Chicago, Illinois, November 27-December 2, 2005.
27. Poster Presentation: Surface Chemistry Proteomics and Biomarker Discovery in Multiple Myeloma. American Society of Hematology (ASH) Annual Meeting, Atlanta, Georgia, December 10-13, 2005.
28. Poster Presentation: Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels—Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission of Newly Diagnosed Multiple Myeloma. American Society of Hematology (ASH) Annual Meeting, Atlanta, Georgia, December 10-13, 2005.
29. Poster Presentation: Killer Immunoglobulin-Like Receptor Ligand (KIR- Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM). American Society of Hematology (ASH) Annual Meeting, Atlanta, Georgia, December 10-13, 2005
30. Poster Presentation: Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels—Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma. American Society of Hematology (ASH) Annual Meeting, Atlanta, Georgia, December 10-13, 2005
31. Oral Presentation (given by Shmuel Yaccoby, lead author). Inhibition of DKK1 Activity Is Associated with Increased Osteoblast Numbers and Bone Formulation, Reduced Osteoclast Activity and Inhibition of Tumor Growth in the SCID-rab Model for Primary Myeloma. American Society of Hematology (ASH) Annual Meeting, Atlanta, Georgia, December 10-13, 2005
32. Published Abstract. Inhibition of DKK1 Activity Is Associated with Increased Osteoblast Numbers and Bone

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

Formulation, Reduced Osteoclast Activity and Inhibition of Tumor Growth in the SCID-rab Model for Primary Myeloma. Abstract #638, *Blood* Vol 106, Issue 11, Nov 16, 2005.

33. Published Abstract: Killer Immunoglobulin-Like Receptor Ligand (KIR- Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM). Abstract #3472, *Blood*, Vol 106, Issue 11, Nov 16, 2005.
34. Published Abstract: Surface Chemistry Proteomics and Biomarker Discovery in Multiple Myeloma. Abstract #2493, *Blood*, Vol 106, Issue 11, Nov 16, 2005.
35. Published Abstract: Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels—Both FDG PET-CT and Serum Clonal Free Light Chain Response Precedes and Predicts the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma. Abstract #3493, *Blood*, Vol 106, Issue 11, Nov 16, 2005.
36. Published Abstract: Investigation of Discrepancies Between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma. Abstract #5079, *Blood*, Vol 106, Issue 11, Nov 16, 2005.
37. Poster presentation: Castleman's Disease: Role of FDG-PET and FDG-PET CT Imaging. 96th Annual Meeting, Radiological Society of North America (RSNA), Chicago, IL, November 26-December 1, 2006.
38. Poster presentation: Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TTS). Board #726-III. 48th Annual Meeting, American Society of Hematology. Orlando, FL, December 9-12, 2006.
39. Poster presentation: Utility of FDG-PET/CT in detecting extramedullary disease in multiple myeloma patients. Reference number: 151075, Publication number 1682. 2009 Annual Meeting, SNM (Society of Nuclear Medicine), Toronto, Canada, June 13-17, 2009.
40. Poster Presentation: Focal lesion number and SUV on PET/CT as they relate to EFS and OS in multiple myeloma (MM) patients. Reference number: 150074. Publication number 644. 2009 Annual Meeting, SNM (Society of Nuclear Medicine), Toronto, Canada, June 13-17, 2009.
41. Poster Presentation: PET and MRI correlation with molecular markers of disease aggressiveness in multiple myeloma. Reference number: 151418. Publication number 136. 2009 Annual Meeting, SNM (Society of Nuclear Medicine), Toronto, Canada, June 13-17, 2009.
42. Poster Presentation: Accuracy of 64-slice coronary CT angiography (CCTA) for the diagnosis of functionally significant coronary artery disease (CAD) on SPECT stress/rest myocardial perfusion scintigraphy (MPS). Reference number: 152685. Publication number 1143. 2009 Annual Meeting, SNM (Society of Nuclear Medicine), Toronto, Canada, June 13-17, 2009.
43. Poster presentation: Utility of FDG-PET/CT in detecting extramedullary disease in multiple myeloma patients. Reference number: 151075, Publication number 1682. 2009 Annual Meeting, SNM (Society of Nuclear Medicine), Toronto, Canada, June 13-17, 2009.

CURRICULUM VITAE

RONALD C, WALKER, MD, FACNM, FACR

44. Poster Presentation: Focal lesion number and SUV on PET/CT as they relate to EFS and OS in multiple myeloma (MM) patients. Reference number: 150074. Publication number 644. 2009 Annual Meeting, SNM (Society of Nuclear Medicine), Toronto, Canada, June 13-17, 2009.
45. Poster Presentation: PET and MRI correlation with molecular markers of disease aggressiveness in multiple myeloma. Reference number: 151418. Publication number 136. 2009 Annual Meeting, SNM (Society of Nuclear Medicine), Toronto, Canada, June 13-17, 2009.
46. Poster Presentation: Accuracy of 64-slice coronary CT angiography (CCTA) for the diagnosis of functionally significant coronary artery disease (CAD) on SPECT stress/rest myocardial perfusion scintigraphy (MPS). Reference number: 152685. Publication number 1143. 2009 Annual Meeting, SNM (Society of Nuclear Medicine), Toronto, Canada, June 13-17, 2009.
47. Poster Presentation: ^{68}Ga -DOTA-Octreotate PET/CT Imaging for Neuroendocrine Tumors: A New Trial in the United States. Annual Meeting, North American Neuroendocrine Tumor Society (NANETS), Santa Fe, NM, Oct 29 – 30, 2010
48. Poster Presentation: Reproducibility of Volumetric Computed Tomography (VCT) of Stable Calcified Pulmonary Nodules. Reference number: 2306. 2012 Annual Meeting, Society of Nuclear Medicine, June 2012, Miami, FL, USA.
49. Poster Presentation: First Report of Measured Human Dosimetry with ^{68}Ga -DOTATATE. Reference number: 1514. 2012 Annual Meeting, Society of Nuclear Medicine, June 2012, Miami, FL, USA.
50. Poster Presentation: Deppen SA, Aldrich MC, **Walker R**, et al. "A new model improves lung cancer prediction in the preoperative evaluation of patients with suspicious lung lesions." American Association for Cancer Research. Annual Meeting, April 6-10, 2013
51. Poster Presentation: Gifford A, Kullberg J, Berglund J, Towse TF, **Walker RC**, Avison M, Welsh B. Detection of Brown Adipose Tissue in Adult Humans Using Fat-Water MRI with Validation by Cold-activated PET. International Society for Magnetic Resonance in Medicine (ISMRM) 2013 Annual Meeting, April 20 – 26, 2013, Salt Lake City, UT
52. Poster Presentation: Stephen Deppen PhD, Adam Bobbey MD, Jeff Clanton DPh, Martin Sandler MD, Dominique Delbeke MD PhD, **Ronald Walker MD**: Safety of ^{68}Ga -DOTATATE PET/CT in Patients with Neuroendocrine Tumors. 2015 World Molecular Imaging Conference, Honolulu, HI, September 2 – 5, 2015.
53. Oral Presentation: Stephen Deppen PhD, Adam Bobbey MD, Jeff Clanton DPh, Martin Sandler MD, Dominique Delbeke MD PhD, Ronald Walker MD. Clinical Trial: Efficacy of ^{68}Ga -DOTATATE PET/CT in Patients with Neuroendocrine Tumors. 2015 World Molecular Imaging Conference, Honolulu, HI, September 2 – 5, 2015.

Invited Lectures (Local, State and Regional):

1. Skeletal Scintigraphy, Arkansas Chapter of ACR, Fall Meeting, 1989, Little Rock, Arkansas

CURRICULUM VITAE
RONALD C, WALKER, MD, FACNM, FACR

2. Invited Speaker, Arkansas Chapter of ACR, Fall Meeting, 1989, Skeletal Scintigraphy, Little Rock, Arkansas
3. Small Parts Ultrasound. Ultrasound Update 1993, Annual Meeting, Arkansas Chapter of the American College of Radiology, Little Rock, Arkansas, November 6, 1993.
4. Nuclear Medicine and the Internet, 43rd Annual Meeting of the Southwestern Chapter of the Society of Nuclear Medicine, Houston, Texas, March 1998.
5. Cardiac Nuclear Imaging, MUGA Scanning and Radionuclide Ventriculography, Arkansas Chapter of ACR, Hot Springs, Arkansas, April, 1998.
6. Role of PET Imaging in the Diagnosis of Lung Cancer. Annual Meeting of the Arkansas Radiological Society, Little Rock, Arkansas April 23, 2005.
7. PET-CT Imaging of Colorectal Cancer. Annual Meeting of the Southeastern Chapter of the Society of Nuclear Medicine, Atlanta, Georgia, September 16-19, 2005.
8. PET-CT in Evaluation of Gynecological Malignancies. Annual Meeting of the Southeastern Chapter of the Society of Nuclear Medicine, Atlanta, Georgia, September 16-19, 2005.
9. PET/CT for Detecting Infection and Monitoring Treatment Response, 52nd Annual Meeting, Southwestern Chapter, SNM, Ft. Worth, TX, 3/30/07 - 04/01/07
10. PET-CT Imaging of Multiple Myeloma. Southeastern Chapter - SNM Annual Meeting, Atlanta, GA 25 – 28 October, 2007.
11. PET-CT Imaging of Infection in the Immune-Compromised Patient. Southeastern Chapter - SNM Annual Meeting, Atlanta, GA 25 – 28, October, 2007.
12. CT Case Reviews: Head and Neck Cancer. Southwestern Chapter – SNM Annual Meeting, Little Rock, AR March 28, 2008
13. Named Lectureship: Ralph Gorten Lecture in Nuclear Cardiology: Applications in Nuclear Medicine. 54th Annual Meeting of the Southwestern Chapter of the Society of Nuclear Medicine, Omni Hotel, Houston, TX, March 22, 2009.
14. CT Case Reviews: Head and Neck Cancer. Southwestern Chapter – SNM Annual Meeting, Ft Worth, TX March 20, 2010

Invited Lectures (National/International):

1. Innovative Imaging Approaches: PET and Its Applications. 20th International Neurotoxicology Conference, Little Rock, AR, November 18-21, 2003.
2. FDG PET Scanning in Multiple Myeloma. Society of Nuclear Medicine Annual Meeting, New Orleans, LA, June 21-25,

CURRICULUM VITAE
RONALD C, WALKER, MD, FACNM, FACR

2003.

3. FDG PET Scanning in Multiple Myeloma. Society of Nuclear Medicine Mid-Winter and Educational Symposium, Anaheim, CA, February 7, 2004.
4. FDG PET/CT Scanning in Multiple Myeloma. Annual Meeting of the Society of Nuclear Medicine, Philadelphia, PA, June 20, 2004
5. FDG-PET scanning in staging and response evaluation. Focus on Myeloma and Plasma Cell Disorders, January 21-22, 2005, Las Vegas, NV.
6. Radiology of fungal infections: when can you tell whether the patient is improving? Focus on Fungal Infection 17 San Diego: 7-9 March 2007.
7. PET/CT: A new and powerful imaging tool for the diagnosis of serious infections, even during severe immune suppression. Focus on Fungal Infection 17 San Diego: 7-9 March 2007.
8. Intravenous CT Contrast: Is It For Everybody? SNM PET Center of Excellence Course: Best Practices in PET/CT, 2008 SNM Annual Meeting, New Orleans, LA, June 14, 2008
9. Go Negative or Go Positive? The Facts about Oral Contrast. SNM PET Center of Excellence Course: Best Practices in PET/CT, 2008 SNM Annual Meeting, New Orleans, LA, June 14, 2008
10. PET Use in Cancer. Association of VA Hematology/Oncology (AVAHO) 4th ANNUAL MEETING, September 13, 2008 Vanderbilt Marriott Hotel, Nashville, TN.
11. Clinical Applications of New Imaging Tools for Infection. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 12– 15, 2009.
12. MRI Correlation in the Brain and Neck with PET/CT. 2010 Annual Conjoint ACNM/SNM Mid-Winter Meeting, Albuquerque, NM, January 27, 2010.
13. CT of the Head and Neck. 55th Annual Meeting of the Southwestern Chapter of the SNM, Fort Worth, TX, March 19-21, 2010
14. ⁶⁸Ga-DOTATATE PET/CT imaging – Initial Vanderbilt experience ACNM/SNM Mid-Winter Meeting, Orlando, FL, January 26-29, 2012
15. In the wake of the National Lung Screening Trial - CT and PET/CT of indeterminate lung nodules Aaron Jessop, MD & Ronald C. Walker, MD, ACNM/SNM Mid-Winter Meeting, Orlando, FL, January 26-29, 2012
16. Molecular Imaging in Europe and Asia: New Lessons from the Old World – Categorical Seminar. 2012 Annual Meeting of the Society of Nuclear Medicine June 9– 13, 2012, Miami, FL. USA.

CURRICULUM VITAE
RONALD C, WALKER, MD, FACNM, FACR

17. Early Results from Lung Cancer Screening with CT. Radiomics Workshop (hosted by Moffitt Cancer Center, Tampa, FL), Hilton Clearwater Beach Hotel, Clearwater Beach, FL. October 31 – November 3, 2012.
18. The DOTA Debate: Approaches to Imaging Neuroendocrine Tumors. Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8 – 12, 2013. Vancouver, BC, Canada (with panel discussion)
19. Organizer/Moderator, Nuclear Medicine 2 Day Review Course, Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8 – 12, 2013 Vancouver, BC, Canada.
20. Invited Lecture: Imaging and Treatment of Neuroendocrine Tumors, Johns Hopkins University School of Medicine, “Nuclear Molecular Imaging and Therapy: Focus on Value.” March 7-8, 2014, Baltimore MD
21. Organizer/Moderator, Nuclear Medicine 2 Day Review Course, Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 7 – 11, 2014 St Louis, MO.
22. Invited lecture and panel discussion: Third Theranostics World Congress on Gallium 68 and PRRT: “Gallium Approval in the US: Background and Moving Forward: The US Experience. March 12 – 14, 2015, Johns Hopkins University, Baltimore, MD.
23. Named Lecture, Ted Bloch Lecture, Plenary Session, “Imaging and Therapy of Neuroendocrine Tumors.” 60th Annual Meeting of the Southwestern Chapter, Society of Nuclear Medicine and Molecular Imaging Annual Meeting, April, 10 – 12, 2015, Austin, TX.